SG11201700816YA - Crystal forms of glutaminase inhibitors - Google Patents

Crystal forms of glutaminase inhibitors

Info

Publication number
SG11201700816YA
SG11201700816YA SG11201700816YA SG11201700816YA SG11201700816YA SG 11201700816Y A SG11201700816Y A SG 11201700816YA SG 11201700816Y A SG11201700816Y A SG 11201700816YA SG 11201700816Y A SG11201700816Y A SG 11201700816YA SG 11201700816Y A SG11201700816Y A SG 11201700816YA
Authority
SG
Singapore
Prior art keywords
crystal forms
glutaminase inhibitors
glutaminase
inhibitors
crystal
Prior art date
Application number
SG11201700816YA
Inventor
Timothy F Stanton
James J Springer
Jacqueline N Williams
Original Assignee
Calithera Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences Inc filed Critical Calithera Biosciences Inc
Publication of SG11201700816YA publication Critical patent/SG11201700816YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201700816YA 2014-08-07 2015-08-07 Crystal forms of glutaminase inhibitors SG11201700816YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462034547P 2014-08-07 2014-08-07
PCT/US2015/044301 WO2016022969A1 (en) 2014-08-07 2015-08-07 Crystal forms of glutaminase inhibitors

Publications (1)

Publication Number Publication Date
SG11201700816YA true SG11201700816YA (en) 2017-02-27

Family

ID=55264662

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201700816YA SG11201700816YA (en) 2014-08-07 2015-08-07 Crystal forms of glutaminase inhibitors

Country Status (13)

Country Link
US (2) US10316030B2 (en)
EP (1) EP3193876B1 (en)
JP (3) JP6889101B2 (en)
KR (1) KR20170082494A (en)
CN (1) CN106999490A (en)
AU (2) AU2015300825B2 (en)
BR (1) BR112017002403A2 (en)
CA (1) CA2957225A1 (en)
EA (1) EA037738B1 (en)
IL (1) IL250391B (en)
MX (1) MX2017001620A (en)
SG (1) SG11201700816YA (en)
WO (1) WO2016022969A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008039489A2 (en) 2006-09-26 2008-04-03 Celgene Corporation 5-substituted quinazolinone derivatives as antitumor agents
DK2683708T3 (en) 2011-03-11 2018-01-29 Celgene Corp SOLID FORMS OF 3- (5-AMINO-2-METHYL-4-OXO-4H-QUINAZOLIN-3-YL) -PIPERIDIN-2,6-DION AND PHARMACEUTICAL COMPOSITIONS AND APPLICATIONS THEREOF
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
ES2814952T3 (en) 2012-09-04 2021-03-29 Celgene Corp 3- (5-amino-2-methyl-4-oxoquinazolin-3 (4H) -yl) piperidine-2-6-dione isotopologues and methods of their preparation
EP3954686A1 (en) 2012-11-16 2022-02-16 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
JP6798890B2 (en) 2014-06-13 2020-12-09 キャリセラ バイオサイエンシーズ， インコーポレイテッド Combination therapy with glutaminase inhibitors
CA2957225A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
EA037152B1 (en) * 2015-03-30 2021-02-11 Калитера Байосайенсиз, Инк. Method of treating cancer
AU2016246521B2 (en) 2015-04-06 2020-07-09 Calithera Biosciences, Inc. Treatment of lung cancer with inhibitors of glutaminase
CA3000996A1 (en) 2015-10-05 2017-04-13 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
CN110139649A (en) 2016-08-25 2019-08-16 卡利泰拉生物科技公司 With the combination treatment of glutamine enzyme inhibitor
EP3503893A4 (en) 2016-08-25 2020-04-29 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
WO2019089854A1 (en) * 2017-10-31 2019-05-09 President And Fellows Of Harvard College Methods and compositions for treating acute myeloid leukemia
EP3946601A1 (en) * 2019-03-26 2022-02-09 Tonix Pharma Holdings Limited Salt forms of s-(n, n-diethylcarbamoyl)glutathione
CN114295836A (en) * 2021-12-22 2022-04-08 融智生物科技（青岛）有限公司 Computing equipment, storage medium and glioma IDH typing detection device and system

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1019519A (en) 1911-07-11 1912-03-05 Oscar Martin Polin Apparatus for making backing for teeth.
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
ES2302881T3 (en) 1997-07-29 2008-08-01 Alcon Laboratories, Inc. OPHTHALMIC COMPOSITIONS CONTAINING GALACTOMANANA AND BORATE POLYMERS.
US5955476A (en) 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
US6110973A (en) 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
AU2002305926A1 (en) 2001-02-05 2002-10-08 Exegenics Inc. Cysteine protease inhibitors
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
DK1654002T4 (en) 2003-08-07 2014-02-17 Allergan Inc Compositions for applying therapeutic agents to the eyes
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
ES2367311T3 (en) 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. MAP-2 PROTEOLYTIC DEGRADATION PRODUCTS AS DIAGNOSTIC BIOMARCATORS FOR NEURAL INJURIES.
JP5567339B2 (en) 2006-09-15 2014-08-06 セルジーン コーポレイション N-methylaminomethylisoindole compound, composition containing the same, and method of using the same
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
WO2009104696A1 (en) 2008-02-19 2009-08-27 株式会社アーネストメディスン Oral or enteral composition useful for recovery of physical functions
US8716314B2 (en) 2009-02-11 2014-05-06 Celgene Corporation Isotopologues of thalidomide
WO2010093434A1 (en) 2009-02-11 2010-08-19 Celgene Corporation Isotopologues of lenalidomide
SI3202461T1 (en) 2010-02-11 2019-05-31 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
WO2012006506A1 (en) 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
WO2012068512A1 (en) 2010-11-18 2012-05-24 Deuteria Pharmaceuticals Llc 3-deutero-pomalidomide
US9045417B2 (en) 2011-01-14 2015-06-02 Celgene Corporation Isotopologues of isoindole derivatives
CA2742342A1 (en) 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
FI20115876A0 (en) 2011-09-06 2011-09-06 Turun Yliopisto Combination therapy
JP5712882B2 (en) * 2011-09-28 2015-05-07 株式会社豊田自動織機 Electric motor for electric compressor
CN103030597B (en) 2011-09-30 2014-10-01 南昌滨西科技有限公司 Kidney type glutaminase inhibitor as well as preparation method and application kidney type glutaminase inhibitor
CA2856386C (en) * 2011-11-21 2022-05-31 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
AU2013266243A1 (en) 2012-05-24 2014-12-18 Beth Israel Deaconess Medical Center, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic Kras-associated cancer
SG11201501653RA (en) 2012-09-10 2015-04-29 Celgene Corp Methods for the treatment of locally advanced breast cancer
US9618514B2 (en) 2012-09-17 2017-04-11 Agios Pharmaceuticals, Inc Methods of evaluating patients using E-cadherin and vimentin
EP3954686A1 (en) 2012-11-16 2022-02-16 Calithera Biosciences, Inc. Heterocyclic glutaminase inhibitors
CA2892089A1 (en) 2012-11-21 2014-05-30 Rene M. Lemieux Glutaminase inhibitors and methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
EP2925318A4 (en) * 2012-12-03 2016-07-13 Calithera Biosciences Inc Treatment of cancer with heterocyclic inhibitors of glutaminase
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
EP3116872A4 (en) 2014-03-14 2017-08-30 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US10221459B2 (en) 2014-05-13 2019-03-05 Case Western Reserve University Compositions and methods of treating cancer harboring PIKC3A mutations
JP6798890B2 (en) 2014-06-13 2020-12-09 キャリセラ バイオサイエンシーズ， インコーポレイテッド Combination therapy with glutaminase inhibitors
WO2016004418A1 (en) 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Glutaminase inhibitor therapy
WO2016014890A1 (en) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
CA2957225A1 (en) 2014-08-07 2016-02-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
WO2016054388A1 (en) 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
WO2016077632A2 (en) 2014-11-13 2016-05-19 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
EA037152B1 (en) 2015-03-30 2021-02-11 Калитера Байосайенсиз, Инк. Method of treating cancer
AU2016246521B2 (en) 2015-04-06 2020-07-09 Calithera Biosciences, Inc. Treatment of lung cancer with inhibitors of glutaminase
CA3000996A1 (en) 2015-10-05 2017-04-13 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
US20180055825A1 (en) 2016-08-25 2018-03-01 Yu Liang Treatment of cancer with inhibitors of glutaminase
CN110139649A (en) 2016-08-25 2019-08-16 卡利泰拉生物科技公司 With the combination treatment of glutamine enzyme inhibitor
EP3503893A4 (en) 2016-08-25 2020-04-29 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
CN110730664A (en) 2017-03-10 2020-01-24 卡利泰拉生物科技公司 Combination therapy with glutaminase inhibitors

Also Published As

Publication number Publication date
CN106999490A (en) 2017-08-01
JP2020037588A (en) 2020-03-12
US10316030B2 (en) 2019-06-11
CA2957225A1 (en) 2016-02-11
EP3193876B1 (en) 2022-01-12
AU2019284149A1 (en) 2020-01-30
EA037738B1 (en) 2021-05-17
IL250391B (en) 2021-10-31
JP2021165286A (en) 2021-10-14
KR20170082494A (en) 2017-07-14
EA201790337A1 (en) 2017-09-29
AU2015300825B2 (en) 2019-10-10
US20190359607A1 (en) 2019-11-28
EP3193876A4 (en) 2017-12-27
EP3193876A1 (en) 2017-07-26
AU2015300825A1 (en) 2017-03-09
US10676472B2 (en) 2020-06-09
WO2016022969A1 (en) 2016-02-11
BR112017002403A2 (en) 2017-12-05
MX2017001620A (en) 2017-05-10
IL250391A0 (en) 2017-03-30
JP2017523991A (en) 2017-08-24
JP6889101B2 (en) 2021-06-18
US20170226101A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
ZA201604272B (en) Inhibitors of glutaminase
IL251584A0 (en) Dihydropyrrolopyridine inhibitors of ror-gamma
IL250391B (en) Crystal forms of glutaminase inhibitors
HK1255427A1 (en) Salts of an lsd1 inhibitor
IL246902B (en) Dihydropyrrolopyridine inhibitors of ror-gamma
GB2542881B (en) Crystal forms of ß-nicotinamide mononucleotide
IL249476A0 (en) Combination therapy with glutaminase inhibitors
ZA201700304B (en) Spirocycloheptanes as inhibitors of rock
HK1254129A1 (en) Methods of administering glutaminase inhibitors
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
EP3494971C0 (en) Salts of erk inhibitors
IL273463A (en) Crystal forms of immunomodulators
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
IL253018A0 (en) Crystal forms of apomorphine and uses thereof
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
EP3212611A4 (en) Crystal forms of verapamil hydrochloride
EP3164195A4 (en) Glutaminase inhibitor therapy
GB201421812D0 (en) New therapeutic uses of enzyme inhibitors
GB201410529D0 (en) New therapeutic uses of enzyme inhibitors